A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency

Trial Profile

A Randomised, Controlled, Observer-blinded Phase III Clinical Trial to Compare the Effect of Intravenous Ferric Carboxymaltose to Placebo on Exercise Capacity and Cardiac Function in Patients With Chronic Heart Failure and Iron Deficiency

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2015

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Heart failure; Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms EFFICACY-HF
  • Sponsors Vifor Pharma
  • Most Recent Events

    • 28 Apr 2012 Additional trial location (Germany) identified as reported by European Clinical Trials Database.
    • 08 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top